Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Tiral of Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection (VDJ001) in the Treatment of Idiopathic Multicentric Castleman Disease (iMCD)

NCT07872423 is registered in ClinicalTrials.gov with Beijing VDJBio Co., LTD. as lead sponsor.

NCT NCT07872423
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872423 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Tiral of Recombinant Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody Injection (VDJ001) in the Treatment of Idiopathic Multicentric Castleman Disease (iMCD)
Lead sponsor
Beijing VDJBio Co., LTD.
Phase
Phase 3
Overall status
Recruiting
Start date
January 27, 2025
Completion date
June 30, 2027
Enrollment
45 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

anti il-6r, castleman's disease, multicentric